Low Libido in Men: Causes, Diagnosis, and Treatments That Work

What “Low Libido” Means

Sexual desire includes interest, thoughts, fantasies, motivation, and responsiveness to sexual cues. Frequency varies greatly between people and across life stages. A lower frequency is not automatically a disorder. The clinically important question is whether the change is persistent, unwanted, distressing, or interfering with the person's well-being or relationship.

Desire can also be responsive rather than spontaneous. Some men rarely think about sex without a cue but experience interest after affection or stimulation begins. That pattern can be normal. A diagnosis should not be built from a partner's preferred frequency, a commercial “low T” checklist, or one week of reduced interest during stress or illness.

Low desire should be separated from erection and ejaculation symptoms. A man may want sex but avoid it because erections are unreliable, ejaculation is painful or delayed, penile curvature causes pain, or he fears another disappointing encounter. In that case desire may be secondarily reduced, while the primary problem lies elsewhere.

The Most Useful First Questions

The timeline often narrows the cause more efficiently than a large laboratory panel. Clinicians ask whether desire was always low or changed recently, whether the change occurs in every context or only with one partner, and whether morning or spontaneous erections changed at the same time. They also ask about mood, pleasure outside sex, fatigue, sleep, pain, alcohol and drug use, fertility plans, relationship safety, and recent illness.

A medication timeline is essential. The relevant question is not just “what do you take?” but what started, stopped, or changed dose before the symptom appeared. Antidepressants, opioids, antipsychotics that raise prolactin, exogenous testosterone or anabolic steroids, and some cardiovascular or neurologic drugs can affect desire, arousal, orgasm, or erections through different pathways.

Physical examination is selected from the presentation. Testicular size or a mass, gynecomastia, reduced body hair, visual-field symptoms, thyroid findings, obesity, vascular disease, or signs of chronic illness can direct testing. Telehealth can collect a detailed history, but a new mass, pain, or neurologic sign requires an appropriate in-person examination.

Testosterone: When and How to Test

The Endocrine Society recommends diagnosing hypogonadism only when symptoms or signs consistent with testosterone deficiency coexist with unequivocally and consistently low testosterone 1. Low desire is compatible with hypogonadism, but it is not specific enough to diagnose it.

Total testosterone is measured in the morning using a reliable assay and repeated on another morning if low. Acute illness, substantial calorie restriction, poor sleep, glucocorticoids, opioids, and laboratory variability can transiently lower the result. In shift workers, timing should reflect the main sleep period rather than blindly using a clock cutoff.

The American Urological Association uses total testosterone below 300 ng/dL as a reasonable cutoff supporting diagnosis, but still requires symptoms and repeat measurement 2. The number should not be applied without the laboratory range, age and clinical context. A result of 299 is not biologically different from 301.

Free testosterone is most useful when total testosterone is near the lower limit or sex-hormone-binding globulin is likely altered, such as with obesity, aging, thyroid disease, liver disease, HIV, or certain medicines. Direct analog free-testosterone assays can be unreliable. Equilibrium dialysis or a validated calculation using total testosterone, SHBG, and albumin is preferred 1.

What LH, FSH, Prolactin, and Thyroid Tests Add

Once low testosterone is confirmed, LH and FSH help distinguish primary testicular dysfunction from hypothalamic or pituitary dysfunction. Low testosterone with high gonadotropins supports primary hypogonadism. Low testosterone with low or inappropriately normal gonadotropins supports central hypogonadism. This distinction affects cause evaluation, fertility treatment, and whether pituitary testing is needed.

Prolactin is useful when testosterone is low with low or normal LH, when there is galactorrhea, headache or visual change, or when a medication may raise prolactin. There is no universal rule that every value above 25 ng/mL requires immediate MRI. Mild elevations may reflect stress, medications, kidney disease, hypothyroidism, macroprolactin, or collection conditions. The 2023 Pituitary Society consensus recommends interpreting the degree, symptoms, repeat measurement when appropriate, medication causes, and imaging context together 3.

TSH is reasonable when symptoms or history suggest thyroid disease or when the initial assessment remains unexplained. Both hyperthyroidism and hypothyroidism can affect sexual function, but a special TSH target of 0.5 to 2.5 mIU/L is not a universal low-libido treatment. Estradiol is not required in every initial panel; it is selected when gynecomastia, unusual breast symptoms, liver disease, or another indication exists.

CBC, metabolic testing, HbA1c, lipids, sleep-apnea assessment, or iron studies can be useful when the history supports them. The previous page's fixed 12-test panel, price promise, and claim that it resolves more than 80% of cases were unsupported and have been removed.

Depression, Anxiety, Stress, and Relationships

Depression can reduce interest, pleasure, energy, self-esteem, and responsiveness to sexual cues. Sexual dysfunction and depression have a bidirectional association, meaning either can worsen the other 4. Screening for depression and suicide risk is therefore part of a low-libido assessment, especially when desire loss accompanies withdrawal from other activities.

Anxiety can shift attention toward performance monitoring and away from pleasurable cues. Trauma, body-image concerns, sexual orientation or identity conflict, fear of pregnancy or infection, relationship resentment, and lack of privacy can also change desire without a hormone disorder. These causes are not “all in the head”; they are clinically meaningful contributors that require the right form of care.

Individual psychotherapy, couples therapy, or sex therapy may help when mood, avoidance, communication, trauma, or situational patterns are central. The evidence base varies by intervention and diagnosis, so a website should not promise a fixed percentage improvement after 12 weeks. Treatment is matched to the formulation rather than prescribed as a generic libido exercise.

Medication-Related Low Desire

Antidepressant-related sexual dysfunction can involve desire, arousal, erection, orgasm, or ejaculation. A meta-analysis found substantial variation across agents, with many SSRIs and venlafaxine associated with more treatment-emergent sexual dysfunction than placebo, while bupropion showed a lower signal in the included studies 5. Depression itself can already impair sexual function, so baseline symptoms matter.

Do not abruptly stop an antidepressant. Options can include waiting after a recent start, dose adjustment, changing drugs, or adding a treatment, but evidence is incomplete and relapse or withdrawal risk must be considered. A Cochrane review found the strongest male evidence for PDE5 inhibitors when the antidepressant problem is erectile dysfunction, not necessarily low desire 6.

Chronic opioids can suppress the hypothalamic-pituitary-gonadal axis. A systematic review and meta-analysis estimated hypogonadism in 63% of mostly male opioid users across heterogeneous studies 7. The number should not be applied to every individual opioid, dose, or duration, but it supports checking symptoms and hormones in sustained exposure.

Antipsychotics can raise prolactin, while anabolic steroids and nonprescribed testosterone suppress LH, FSH, and sperm production. Finasteride and dutasteride can cause sexual adverse effects in some users, but published estimates vary and persistent symptoms remain difficult to quantify. Medication changes should balance the original indication and alternatives with the prescriber.

Sleep, Weight, Chronic Disease, and Substance Use

Short sleep can affect mood, energy, relationship bandwidth, and testosterone. In a small laboratory study of ten healthy young men, one week of five-hour sleep opportunities lowered daytime testosterone by about 10% to 15% 8. This study supports sleep as part of assessment, not a promise that seven nights of longer sleep will cure low desire.

Obesity can lower total testosterone partly through lower SHBG and can contribute to sleep apnea, inflammation, vascular disease, and body-image distress. Weight reduction may improve testosterone in men with functional obesity-related hypogonadism, but a GLP-1 drug should not be prescribed solely as a libido medicine. The prior page's claimed STEP-1 testosterone substudy and semaglutide erectile-function study were not supported and have been removed.

Diabetes, cardiovascular disease, chronic pain, kidney or liver disease, neurologic conditions, and cancer treatment can affect desire directly or through fatigue, vascular function, neuropathy, medications, and relationship stress. Alcohol can initially lower inhibition but impair erections and desire with heavier or chronic use. Cannabis and other drugs can have variable effects and should be discussed without assuming one universal response.

When Testosterone Treatment Helps

Testosterone treatment is reasonable for selected men with symptoms plus repeatedly low testosterone after the cause, contraindications, reproductive goals, and monitoring plan are reviewed. Across randomized trials, average improvements in desire and sexual satisfaction are statistically significant but modest, and erythrocytosis risk increases 9.

The TRAVERSE Sexual Function Study enrolled 1,161 men ages 45 to 80 who had low libido, symptoms, and two testosterone concentrations below 300 ng/dL. Testosterone gel produced greater improvements in sexual activity and desire than placebo, sustained through follow-up, but did not meaningfully improve erectile function 10. That finding reinforces the distinction between desire and erections.

TRAVERSE's main cardiovascular trial found testosterone noninferior to placebo for major adverse cardiovascular events in men with confirmed hypogonadism and existing or high cardiovascular risk 11. It did not prove universal cardiovascular safety for younger men, supraphysiologic dosing, bodybuilding use, compounded products, or men without hypogonadism. Pulmonary embolism, atrial fibrillation, and acute kidney injury were observed more often in the testosterone group, which remains relevant to individual counseling.

There is no single “libido target” of 400 to 700 ng/dL that applies to every formulation and patient. Dose timing and reference range differ by gel, injection, oral product, patch, or implant. Treatment aims for a mid-normal physiologic range using formulation-specific monitoring while avoiding excessive hematocrit and other adverse effects 1.

Fertility Changes the Treatment Decision

Exogenous testosterone suppresses pituitary LH and FSH, lowers intratesticular testosterone, and can markedly reduce or stop sperm production. The Endocrine Society recommends against starting testosterone in men planning fertility in the near term 1.

Clomiphene, enclomiphene products, hCG, and gonadotropins are not interchangeable over-the-counter libido treatments. Their role depends on whether central hypogonadism is present, whether the testes can respond, and whether fertility is the goal. The previous page's fixed clomiphene and hCG regimen was unsupported for a general low-libido article and has been removed.

Men who may want biological children should consider semen analysis and reproductive-urology or endocrinology input before testosterone, especially if baseline fertility is uncertain. Recovery after stopping testosterone varies by age, duration, dose, baseline testicular function, and other androgen exposure.

Erectile Dysfunction, Ejaculation Problems, and Peyronie Disease

Erectile dysfunction means difficulty achieving or maintaining an erection, not lack of desire. PDE5 inhibitors improve penile blood flow when sexual stimulation occurs; they do not create sexual interest. The AUA erectile-dysfunction guideline also treats ED as a potential marker of underlying cardiovascular disease and recommends a full medical and sexual history 12.

Premature ejaculation is ejaculation sooner than desired with poor control and distress. Delayed ejaculation is marked delay or absence of ejaculation despite adequate stimulation. Peyronie disease involves penile plaque, curvature, pain, or shortening. Any of these can reduce desire secondarily through anxiety, pain, or avoidance, but each requires its own diagnosis. Detailed drug and procedural protocols belong on condition-specific pages, not inside a low-libido page.

A Cause-Based Treatment Plan

For confirmed hypogonadism, address reversible contributors and consider testosterone only after fertility, risks, and monitoring are discussed. For hyperprolactinemia, identify medication and systemic causes and treat a confirmed prolactinoma according to pituitary guidance. For thyroid disease, treat the thyroid disorder to its evidence-based target rather than treating libido with thyroid hormone.

For antidepressant or opioid effects, work with the prescriber on benefits, risks, alternatives, and safe tapering. For depression, anxiety, trauma, or relationship conflict, use the corresponding mental-health or relationship intervention. For sleep apnea, chronic pain, diabetes, vascular disease, or alcohol misuse, treatment of the underlying condition may improve sexual health even when testosterone is normal.

Improvement does not follow one timetable. Testosterone's average trial effect develops over months, while medication changes, depression treatment, relationship repair, sleep treatment, and recovery from illness have different courses. A lack of response after normalizing testosterone should prompt reconsideration of the diagnosis rather than automatic dose escalation or addition of an aromatase inhibitor.

When to Refer or Seek Faster Evaluation

Endocrinology or urology input is appropriate for very low testosterone with low or normal gonadotropins, persistent unexplained prolactin elevation, testicular abnormality, infertility, complex pituitary history, treatment complications, or uncertainty about diagnosis. Severe headache, visual-field change, double vision, vomiting, or multiple pituitary-hormone abnormalities can require urgent pituitary evaluation.

Acute testicular pain or swelling requires urgent in-person assessment. A new testicular mass, blood in semen with other concerning findings, penile trauma, painful curvature, or erection lasting four hours also needs prompt condition-specific care. New suicidal thinking or severe depression requires immediate mental-health support.